TG Therapeutics announces issuance of permanent J-code for BRIUMVI

TG Therapeutics announced that the U.S. Centers for Medicare & Medicaid Services has issued a permanent J-Code for BRIUMVI, for the treatment of adult patients with relapsing forms of multiple sclerosis. Under the Healthcare Common Procedure Coding System, the BRIUMVI J-Code will become effective July 1, 2023. Michael Weiss, the Company’s Chairman and Chief Executive Officer, stated, "The issuance of a permanent J-Code for BRIUMVI is a significant milestone in our early launch phase. Once in effect, the permanent J-Code will provide a streamlined and efficient reimbursement process, which we believe will facilitate additional patient access. We are encouraged by the early launch of BRIUMVI and look forward to sharing additional details on our first quarter earnings call."